MUC17

MUC17 is a membrane-tethered mucin that forms the protective glycocalyx on the apical brush border of intestinal enterocytes, serving as a critical barrier against bacterial invasion and maintaining epithelial homeostasis. Its surface localization requires complex-type N-glycosylation, scaffolding by PDZK1 via a C-terminal PDZ-binding motif, and apical trafficking mediated by MYO1B, MYO5B, and SNX27; upon cholinergic (carbachol) or inflammatory (TNFα) stimulation, MUC17 undergoes stimulus-specific endocytosis or shedding that coordinately regulates ion transporter trafficking and serves as a bacterial decoy against pathogen adhesion (PMID:12888891, PMID:17990980, PMID:23784542, PMID:31387973, PMID:39661054). The extracellular EGF-like cysteine-rich domains (CRD1-L-CRD2) promote epithelial restitution by stimulating ERK-dependent cell migration and inhibiting apoptosis, while MUC17 suppresses NF-κB signaling through promotion of IκB-α generation (PMID:20211273, PMID:36778111). MUC17 expression is epigenetically silenced by DNMT1/UHRF1-mediated promoter methylation and repressive H3-K9 histone marks, and is induced under hypoxia via HIF1α binding to unmethylated hypoxia-responsive elements; genetic deletion of Muc17 in mice causes spontaneous loss of epithelial barrier integrity and bacterial translocation, phenocopying features of human Crohn's disease (PMID:20926598, PMID:22970168, PMID:39699961).

1. 2002 High

   Establishing the domain architecture of MUC17 as a transmembrane mucin with EGF-like domains, a SEA module, and a cytoplasmic tail resolved the gene's identity as a membrane-tethered mucin distinct from secreted gel-forming mucins.

   Evidence cDNA cloning, sequence analysis, RNA blot, and in situ hybridization

   PMID:11855812

   Open questions at the time

   • No functional role assigned to any domain
   • Post-translational processing of SEA module not addressed
2. 2003 High

   Demonstrating that complex-type N-glycosylation is required for MUC17 surface localization established a quality-control step governing its membrane delivery.

   Evidence Surface biotinylation with N-glycan hydrolases and tunicamycin/brefeldin A inhibitor treatments

   PMID:12888891

   Open questions at the time

   • Specific N-glycosylation sites not mapped
   • Whether glycosylation affects mucin barrier function not tested
3. 2006 High

   Identification of alternate splicing producing membrane-anchored and secreted MUC17 isoforms, together with promoter elements (VDR/RXR, GATA, NF-κB, Cdx-2), revealed transcriptional logic controlling tissue-specific expression.

   Evidence RACE-PCR, in vitro transcription/translation, promoter-reporter analysis

   PMID:16737958

   Open questions at the time

   • Relative abundance of secreted vs. membrane isoform in vivo unknown
   • Individual transcription factor contributions not dissected in vivo
4. 2008 High

   Discovery that PDZK1 scaffolds MUC17 at the brush border via its PDZ-binding motif — and that Pdzk1 knockout displaces the mouse ortholog to intracellular compartments — identified the mechanism anchoring MUC17 at the apical membrane.

   Evidence PDZ domain array, GST pull-down with mass spectrometry, immunostaining in wild-type vs. Pdzk1−/− mouse jejunum

   PMID:17990980

   Open questions at the time

   • Whether PDZK1 loss compromises barrier function not tested
   • Other PDZ partners not excluded
5. 2010 High

   Showing that the EGF-like CRD1-L-CRD2 domain stimulates ERK-dependent cell migration and inhibits apoptosis — while MUC17 knockdown reduces cell-cell adherence — established MUC17 as an active signaling mucin that promotes epithelial restitution.

   Evidence shRNA knockdown, recombinant CRD protein treatment, ERK inhibitor experiments, cell migration and apoptosis assays, domain truncation analysis

   PMID:20211273 PMID:20332014

   Open questions at the time

   • Receptor that transduces the ERK signal not identified
   • In vivo wound-healing relevance not demonstrated at that time
6. 2010 Medium

   Demonstrating that MUC17 promoter DNA methylation and H3-K9 histone modifications control its expression revealed an epigenetic switch that silences MUC17 in non-expressing cell types.

   Evidence Bisulfite sequencing, ChIP for histone marks, methylation inhibitor treatment across multiple cell lines

   PMID:20926598

   Open questions at the time

   • Enzymes responsible for establishing these marks not identified in this study
   • In vivo epigenetic regulation not assessed
7. 2011 Medium

   Loss-of-function experiments showing that MUC17 depletion increases paracellular permeability, induces iNOS/COX-2, and enhances enteroinvasive bacterial invasion established MUC17 as a functional barrier component, not merely a passive glycocalyx element.

   Evidence siRNA knockdown in enterocytes, transepithelial resistance, permeability assay, EIEC invasion assay

   PMID:21393431

   Open questions at the time

   • Whether barrier loss is due to glycocalyx thinning or altered signaling not resolved
   • Single cell-line system
8. 2012 Medium

   Showing that HIF1α induces MUC17 under hypoxia — but only when the HRE is unmethylated — integrated epigenetic and oxygen-sensing pathways into a unified regulatory model.

   Evidence Hypoxic culture, HIF1α pathway analysis, bisulfite sequencing of HRE, 5-aza-2′-deoxycytidine rescue, reporter assays

   PMID:22970168

   Open questions at the time

   • Physiological relevance of hypoxic MUC17 induction in intestinal ischemia not tested in vivo
   • Whether HIF2α also contributes not addressed
9. 2013 High

   Demonstrating that carbachol triggers specific MUC17 endocytosis concomitant with NHE3 internalization and CFTR apical recruitment revealed that MUC17 participates in coordinated ion/mucin trafficking at the brush border.

   Evidence Surface labeling, confocal imaging, pharmacological stimulation, subcellular fractionation in Caco-2 cells and murine enterocytes

   PMID:23784542

   Open questions at the time

   • Molecular machinery linking MUC17-PDZK1 dissociation to endocytosis unknown
   • Whether CFTR recruitment is MUC17-dependent or parallel not determined
10. 2019 High

    Identification of phosphorylated serines (S4428, S4492) in the MUC17 cytoplasmic tail — with S4492 modulating PDZ-binding and apical retention — together with TNFα-induced shedding that yields decoy vesicles blocking EPEC adhesion, established MUC17 as an actively regulated anti-microbial effector.

    Evidence Mass spectrometry phosphosite mapping, site-directed mutagenesis, TNFα stimulation, bacterial adhesion assay in Caco-2 cells

    PMID:31387973

    Open questions at the time

    • Kinase(s) phosphorylating S4428 and S4492 not identified
    • Whether shed MUC17 vesicles function in vivo not tested
11. 2019 Medium

    Showing that MUC17 inhibits NF-κB and prevents H. pylori CagA translocation — and that H. pylori silences MUC17 via DNMT1-dependent methylation — identified MUC17 as a gastric defense factor subverted by pathogen epigenetic manipulation.

    Evidence Gain- and loss-of-function in gastric cancer cells, H. pylori infection, CagA translocation assay, NF-κB reporter, bisulfite sequencing

    PMID:30778796

    Open questions at the time

    • Mechanism linking MUC17 to CagA injection blockade unclear
    • Relevance to in vivo gastric colonization not tested
12. 2023 Medium

    Demonstrating that UHRF1/DNMT1-mediated MUC17 silencing activates NF-κB in EGFR-TKI-resistant cells — and that MUC17 re-expression restores IκB-α via MZF1 — defined a mechanistic link between MUC17 loss and inflammatory signaling in drug resistance.

    Evidence Drug-resistant cell lines, 5-Aza rescue, ChIP, NF-κB reporter, xenograft

    PMID:36778111

    Open questions at the time

    • Direct physical interaction between MUC17 and MZF1 or IκB-α pathway components not shown
    • Generalizability beyond EGFR-TKI resistance context unclear
13. 2024 High

    Genetic deletion of Muc17 in mice proved that MUC17 is essential for small intestinal barrier integrity in vivo: knockout mice exhibit spontaneous bacterial translocation and harbor bacterial communities resembling those in Crohn's disease ileum, directly linking MUC17 loss to IBD-related barrier failure.

    Evidence Muc17 knockout mouse, bacterial challenge, 16S sequencing, histology, comparison with human Crohn's disease ileal biopsies

    PMID:39699961

    Open questions at the time

    • Whether Muc17 loss is compensated by other membrane mucins over time not assessed
    • Causal direction of MUC17 reduction in human CD not established
14. 2025 Medium

    Identification of MYO1B, MYO5B, and SNX27 as regulators of MUC17 apical targeting and brush border turnover mapped the intracellular trafficking machinery that delivers MUC17 to its functional location.

    Evidence siRNA knockdown of MYO1B, MYO5B, SNX27; confocal imaging; biochemical fractionation; bacterial adhesion assay

    PMID:39661054

    Open questions at the time

    • Whether these motors act sequentially or in parallel not resolved
    • Vesicular intermediates carrying MUC17 not characterized

• Key unresolved questions include the identity of the kinase(s) phosphorylating the MUC17 cytoplasmic tail, the receptor that transduces EGF-like domain signaling through ERK, the structural basis of CRD1-L-CRD2 activity, whether shed MUC17 vesicles function as bacterial decoys in vivo, and whether therapeutic re-expression of MUC17 (e.g., via demethylation) can restore barrier function in IBD.
• No kinase identified for S4428/S4492 phosphorylation
• No receptor identified for CRD-mediated ERK signaling
• No structural model of the MUC17 ectodomain